This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Albert-Ludwigs-Universitat Freiburg. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Innovations in Cancer Treatment by Sheng Wang
Introduction
Sheng Wang is a notable inventor based in Freiburg, Germany. He has made significant contributions to the field of cancer treatment through his innovative research. His work focuses on the inhibition of histone methyl transferases, which are crucial in the regulation of gene expression.
Latest Patents
Sheng Wang holds a patent titled "Inhibition of histone methyl transferases to treat cancer." This invention involves an inhibitor selected from a group consisting of a selective KMT9-inhibitor, a selective METTL21A-inhibitor, and a selective METTL21B-inhibitor for use in cancer treatment. KMT9, METTL21A, and METTL21B are characterized for the first time as histone methyl transferases, and their inhibitors can be utilized in therapeutic applications against cancer. He has 1 patent to his name.
Career Highlights
Sheng Wang is affiliated with Albert-Ludwigs-Universität Freiburg, where he conducts his research. His work has garnered attention for its potential impact on cancer therapies, showcasing his dedication to advancing medical science.
Collaborations
Sheng Wang collaborates with fellow researcher Roland Schüle, contributing to the development of innovative solutions in cancer treatment.
Conclusion
Sheng Wang's contributions to the field of cancer treatment through his innovative patent highlight the importance of research in developing effective therapies. His work exemplifies the potential of scientific innovation to address critical health challenges.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile